Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 14/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | GNRHR | P30968 | 1/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373809 | 0.97 | S1PR1 (0.49) | NPSR1S1PR1S1PR3PGRGNRHR | |
| SCHEMBL12373821 | 0.94 | S1PR1 (0.53) | NPSR1S1PR1S1PR3 | |
| SCHEMBL12373804 | 0.94 | S1PR1 (0.48) | NPSR1S1PR1S1PR3PGRGNRHR | |
| SCHEMBL2275493 | 0.91 | S1PR1 (0.44) | NPSR1S1PR1S1PR3PGRPTGES2 | |
| SCHEMBL2276391 | 0.91 | S1PR1 (0.44) | NPSR1S1PR1S1PR3PGRPTGES2 | |
| SCHEMBL2274455 | 0.91 | S1PR1 (0.44) | NPSR1S1PR1S1PR3PGRPTGES2 | |
| SCHEMBL12373800 | 0.89 | NPSR1 (0.47) | NPSR1S1PR1S1PR3GNRHR | |
| SCHEMBL12373811 | 0.86 | S1PR1 (0.44) | NPSR1S1PR1S1PR3GNRHR | |
| SCHEMBL12373812 | 0.86 | S1PR1 (0.43) | NPSR1S1PR1S1PR3PGRGNRHR | |
| SCHEMBL12373790 | 0.86 | S1PR1 (0.52) | S1PR1S1PR3PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | S1PR1, S1PR3, S1PR2 | NPSR1 110/4885S1PR1 1/4885S1PR3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.